The FDA approval is a major value inflection point for Arvinas, likely driving a significant positive stock reaction. Monitor for the selection of a third-party commercialization partner and initial launch metrics. The $50M milestone provides near-term cash, but long-term value depends on commercial uptake and label expansion.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $10.51entry
- T+1 · 7mo ago +2.57%α +2.91% · $10.78
- T+5 · 6mo ago −3.04%α −5.39% · $10.19
- T+20 · 6mo ago −18.36%α −23.65% · $8.58
- T+60 · 4mo ago −21.98%α −25.05% · $8.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breast cancer, the first-ever approved PROTAC therapy. The approval came ahead of the June 5 PDUFA date, and Arvinas will receive a $50M milestone payment from partner Pfizer. This transformative milestone validates the PROTAC platform and provides a new treatment option in a high-need setting.
Key Facts
- FDA approved VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy.
- First-and-only FDA-approved PROTAC (protein degrader) therapy.
- Approval received ahead of the June 5, 2026 PDUFA date.
- In the Phase 3 VERITAC-2 trial, VEPPANU reduced risk of disease progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001) in ESR1-mutated patients.
- Arvinas will receive a $50M development milestone payment from Pfizer, offset by amounts owed to Yale University.
- Arvinas and Pfizer remain on track to select a third-party commercial partner.
Financial Impact
$50 million milestone payment from Pfizer (net of Yale obligations); future commercial revenue potential for a first-in-class drug
Risk Factors
- Commercial execution risk given Arvinas and Pfizer are outsourcing commercialization
- Potential safety concerns (QT prolongation, liver enzyme elevations) may limit use
- Competition from other CDK4/6 inhibitor combinations and emerging therapies
- ESR1-mutant patient population limits addressable market (~40-50% of ER+ patients)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-029210 |
| Document: fdaapprovalpressrelease_.htm | 0001628280-26-029210 |
| Document: 0001628280-26-029210-index-headers.html | 0001628280-26-029210 |
| Document: 0001628280-26-029210-index.html | 0001628280-26-029210 |
| Document: 0001628280-26-029210.txt | 0001628280-26-029210 |
Track record
21 reports on ARVN
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers